Dun & Bradstreet Del Ne (DNB) Shareholder Fort LP Cut Its Holding as Valuation Rose; Amgen (AMGN) Shareholder Kcm Investment Advisors Upped Position by $4.83 Million

Amgen Inc. (NASDAQ:AMGN) Logo

Fort Lp decreased its stake in Dun & Bradstreet Corp Del Ne (DNB) by 21.71% based on its latest 2018Q3 regulatory filing with the SEC. Fort Lp sold 18,336 shares as the company’s stock rose 0.85% while stock markets declined. The hedge fund held 66,130 shares of the consumer services company at the end of 2018Q3, valued at $9.42M, down from 84,466 at the end of the previous reported quarter. Fort Lp who had been investing in Dun & Bradstreet Corp Del Ne for a number of months, seems to be less bullish one the $5.34B market cap company. The stock increased 0.20% or $0.28 during the last trading session, reaching $143.68. About 43,477 shares traded. The Dun & Bradstreet Corporation (NYSE:DNB) has risen 18.35% since January 10, 2018 and is uptrending. It has outperformed by 18.35% the S&P500. Some Historical DNB News: 07/03/2018 – Safe Bulkers, Inc; 21/03/2018 – Strategic Health Services LLC d/b/a Palm Medical Centers, an MBF Healthcare Partners Portfolio Company, Announces the Acquisition of Angel Medical Center; 09/05/2018 – DUN & BRADSTREET 1Q ADJ EPS $1.24, EST. $1.07; 04/05/2018 – Boston Partners Buys New 3.1% Position in Dun & Bradstreet; 10/04/2018 – Kansas CC: In the Matter of the Investigation of Paul Jacob Diehl, Jr., d/b/a Diehl Farms; 26/04/2018 – DnB ASA 1Q Net Pft NOK5.43B; 03/05/2018 – REG-DB ETC Upload of documents on the National Storage Mechanism; 14/03/2018 – FBO:Veteran Aff: Veterans Affairs Contract Award – Z–603-CSI-803 – DB Site Prep HFO MRI Replacement Bldg.-213A – 9314; 27/03/2018 – RI PUC: 4812 Irontrust Properties, LCC d/b/a Inrontrust Networks Application for registration as Class VI Telecommication; 08/04/2018 – DB SPVY BOARD IS SAID TO NAME VON ROHR, RITCHIE DEPUTIES: HB

Kcm Investment Advisors Llc increased its stake in Amgen Inc (AMGN) by 161.59% based on its latest 2018Q3 regulatory filing with the SEC. Kcm Investment Advisors Llc bought 23,342 shares as the company’s stock declined 4.15% with the market. The institutional investor held 37,787 shares of the biological products (no diagnostic substances) company at the end of 2018Q3, valued at $7.83M, up from 14,445 at the end of the previous reported quarter. Kcm Investment Advisors Llc who had been investing in Amgen Inc for a number of months, seems to be bullish on the $128.63B market cap company. The stock increased 0.74% or $1.49 during the last trading session, reaching $201.86. About 896,864 shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 11.57% since January 10, 2018 and is uptrending. It has outperformed by 11.57% the S&P500. Some Historical AMGN News: 22/05/2018 – AMGEN INC – ALL OF DIRECTOR NOMINEES WERE RE-ELECTED TO BOARD AT ANNUAL MEETING OF STOCKHOLDERS; 10/04/2018 – AMGEN INC – FOLLOWING RECENT U.S. FEDERAL TAX REFORM, CO MADE DECISION TO LOCATE NEW PLANT IN U.S. RHODE ISLAND; 30/04/2018 – Amgen Receives Positive CHMP Opinion to Add Overall Survival Results From the Phase 3 ASPIRE Study to KYPROLIS(R) (carfilzomib) Label; 16/05/2018 – AMGEN GETS EC APPROVAL FOR REPATHA┬« (EVOLOCUMAB) TO PREVENT HEA; 17/05/2018 – NOVARTIS AG NOVN.S – EMA MARKETING AUTHORIZATION APPLICATION FOR AIMOVIG IS UNDER REVIEW. NOVARTIS EXPECTS APPROVAL IN EU IN COMING MONTHS; 23/03/2018 – AMGEN INC – CHMP POSITIVE OPINION FOR ABP 980 WILL NOW BE REVIEWED BY EUROPEAN COMMISSION; 17/05/2018 – BEYONDSPRING TO PRESENT POSITIVE DATA FROM PROSPECTIVE PHASE 2 TRIAL COMPARING PLINABULIN TO NEULASTA FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA AT 2018 ASCO ANNUAL MEETING; 23/03/2018 – AMGEN GETS POSITIVE CHMP OPINION RECOGNIZING REPATHA┬« (EVOLOCUM; 11/05/2018 – Amgen Presenting at Bank of America Conference May 15; 03/04/2018 – Amgen Inc. | anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct | N/A | 04/02/2018 | Treatment of glioblastoma | Designated | NFDA | N/A | | N/A

More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: Nasdaq.com which released: “Health Care Sector Update for 12/28/2018: APHA, MESO, HTGM, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on December 28, 2018, also Nasdaq.com with their article: “Health Care Sector Update for 12/12/2018: SGYP, NBIX, MRNS, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” published on December 12, 2018, Nasdaq.com published: “Health Care Sector Update for 12/27/2018: AXSM, HSIC, BSX, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on December 27, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Nasdaq.com and their article: “Health Care Sector Update for 12/31/2018: VTVT, ADMP, MBOT, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” published on December 31, 2018 as well as Nasdaq.com‘s news article titled: “Forget GlaxoSmithKline, Eli Lilly Is a Better Big Pharma Stock – Nasdaq” with publication date: December 29, 2018.

Since November 29, 2018, it had 0 insider buys, and 2 sales for $4.27 million activity. $3.91M worth of Amgen Inc. (NASDAQ:AMGN) was sold by Jacks Tyler.

Among 27 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 16 Hold. Therefore 41% are positive. Amgen Inc. had 101 analyst reports since August 3, 2015 according to SRatingsIntel. Cowen & Co maintained it with “Buy” rating and $204.0 target in Thursday, February 1 report. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. On Wednesday, April 5 the stock rating was downgraded by Jefferies to “Hold”. As per Wednesday, October 31, the company rating was maintained by Morgan Stanley. The stock has “Market Perform” rating by BMO Capital Markets on Thursday, October 26. The stock of Amgen Inc. (NASDAQ:AMGN) has “Hold” rating given on Thursday, October 26 by RBC Capital Markets. Jefferies maintained the shares of AMGN in report on Thursday, September 28 with “Buy” rating. On Tuesday, July 11 the stock rating was reinitiated by Jefferies with “Buy”. BMO Capital Markets downgraded Amgen Inc. (NASDAQ:AMGN) on Wednesday, July 26 to “Market Perform” rating. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Overweight” rating by Morgan Stanley on Tuesday, December 15.

Kcm Investment Advisors Llc, which manages about $2.95B and $1.75B US Long portfolio, decreased its stake in Intl Business Machines Corp (NYSE:IBM) by 2,689 shares to 14,477 shares, valued at $2.19 million in 2018Q3, according to the filing. It also reduced its holding in Intel Corp (NASDAQ:INTC) by 6,716 shares in the quarter, leaving it with 367,839 shares, and cut its stake in Lowe’s Cos Inc (NYSE:LOW).

Investors sentiment decreased to 0.87 in Q3 2018. Its down 0.12, from 0.99 in 2018Q2. It dropped, as 49 investors sold AMGN shares while 550 reduced holdings. 130 funds opened positions while 393 raised stakes. 470.42 million shares or 2.68% less from 483.36 million shares in 2018Q2 were reported. Raab Moskowitz Asset Management Limited Liability Corp holds 494 shares or 0.04% of its portfolio. M Securities accumulated 0.15% or 2,813 shares. Arrow has 25,230 shares for 1.1% of their portfolio. Jump Trading Limited Com holds 0.01% or 1,061 shares in its portfolio. Cibc Ww Markets reported 73,720 shares or 0.07% of all its holdings. Arete Wealth Advsrs Lc holds 21,082 shares. Illinois-based Allstate has invested 0.01% in Amgen Inc. (NASDAQ:AMGN). Stone Run Lc invested 0.13% of its portfolio in Amgen Inc. (NASDAQ:AMGN). 21,033 were reported by Balyasny Asset Mgmt Llc. Arizona State Retirement System invested 0.31% in Amgen Inc. (NASDAQ:AMGN). Pinnacle Assocs Ltd holds 0.3% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 69,319 shares. Jane Street Grp Limited Liability Corporation has invested 0.03% in Amgen Inc. (NASDAQ:AMGN). Thompson Siegel And Walmsley Limited Liability reported 1,876 shares. Waters Parkerson & Co Ltd has invested 0.13% in Amgen Inc. (NASDAQ:AMGN). The California-based Franklin Inc has invested 0.39% in Amgen Inc. (NASDAQ:AMGN).

Among 8 analysts covering Dun & Bradstreet (NYSE:DNB), 0 have Buy rating, 0 Sell and 8 Hold. Therefore 0 are positive. Dun & Bradstreet had 20 analyst reports since November 4, 2015 according to SRatingsIntel. JP Morgan maintained it with “Neutral” rating and $124 target in Wednesday, February 14 report. The stock of The Dun & Bradstreet Corporation (NYSE:DNB) has “Neutral” rating given on Friday, January 20 by Goldman Sachs. The stock of The Dun & Bradstreet Corporation (NYSE:DNB) has “Equal-Weight” rating given on Friday, August 10 by Barclays Capital. Wells Fargo maintained The Dun & Bradstreet Corporation (NYSE:DNB) on Monday, June 25 with “Market Perform” rating. The stock of The Dun & Bradstreet Corporation (NYSE:DNB) has “Buy” rating given on Friday, May 11 by Robert W. Baird. The firm has “Hold” rating given on Wednesday, February 14 by Piper Jaffray. Robert W. Baird maintained it with “Neutral” rating and $145 target in Thursday, August 9 report. The rating was maintained by Stifel Nicolaus on Tuesday, July 25 with “Hold”. The rating was maintained by Piper Jaffray on Tuesday, January 23 with “Hold”. The stock of The Dun & Bradstreet Corporation (NYSE:DNB) has “Hold” rating given on Wednesday, August 2 by Piper Jaffray.

Analysts await The Dun & Bradstreet Corporation (NYSE:DNB) to report earnings on February, 11. They expect $3.76 earnings per share, up 16.77% or $0.54 from last year’s $3.22 per share. DNB’s profit will be $139.61M for 9.55 P/E if the $3.76 EPS becomes a reality. After $1.85 actual earnings per share reported by The Dun & Bradstreet Corporation for the previous quarter, Wall Street now forecasts 103.24% EPS growth.

Amgen Inc. (NASDAQ:AMGN) Institutional Positions Chart